The potential therapeutic target of progesterone signaling offers a non-surgical prophylactic approach to prevent ovarian and breast cancer in BRCA1 mutation carriers and provides a comprehensive overview of the complex interplay of genetic mutations, DNA repair mechanisms, and hormone signaling pathways in cancer development [55,56]. Here, BRCA1 is linked to breast carcinoma.